Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo Ketoprofen Patch Fails Two Phase III Studies; Firm Revises 2007 Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

Endo awaits results from another Phase III efficacy study expected by Aug. 1 before it makes a go/no go decision on the product.

You may also be interested in...



Alpharma Ups Ante With Phase III Embeda Proof

Pain drug’s data could help lure more than King to the table.

Alpharma Ups Ante With Phase III Embeda Proof

Pain drug’s data could help lure more than King to the table.

Endo Financials Strong, But Shareholder Calls For Sale Of Company

CEO stepping down and no R&D leader on board, as officials evaluate pipeline.

Related Content

Topics

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel